ClinicalTrials.gg
CompletedNCT00002410Updated Jun 24, 2005

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

A Phase 3 interventional study of Indinavir sulfate and Lamivudine in HIV Infections, sponsored by Dupont Merck. Completed at 41 sites in 2 countries. Open to participants aged 13 Years to 60 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Dupont Merck · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
13 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing indinavir in HIV Infections — none open to participants now, none under way, none of them phase 3. Indinavir · HIV Infections.

Phase 3
10 of 49
none open now
Registered
1st of 49
by date
Lead sponsor
2 of 49
Dupont Merck

Among the 49 studies testing indinavir in HIV Infections, this one is one of 10 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 49 studies testing indinavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About indinavir

Indinavir: first FDA approval 1996 (CRIXIVAN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 13 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing indinavir in HIV Infections as a file.
02

Study summary

The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC); and (3) indinavir plus ZDV plus 3TC. This study also examines the resistance HIV may have to these drugs and if these drugs are effective over a long period of time.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Zidovudine
  • Drug Resistance, Microbial
  • HIV Protease Inhibitors
  • Lamivudine
  • Indinavir
  • Genotype
  • Reverse Transcriptase Inhibitors
  • efavirenz
04

Who can participate

Ages eligible
13 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Exclusion Criteria

Concurrent Medication:

Excluded:

  • Terfenadine, astemizole, cisapride, triazolam, or midazolam (competition for the enzyme cytochrome P-450 3A4 [] by indinavir could result in inhibition of metabolic breakdown of these drugs and create the potential for serious and/or life threatening events [i.e., cardiac arrhythmia, prolonged sedation]).
  • Rifampin or rifabutin (prohibited because of potential drug interaction with indinavir).
  • Ketoconazole, itraconazole, and clarithromycin.
  • Concomitant systemic therapy for acute opportunistic infection or .

Excluded:

less than 12 months.

Prior Medication:

Excluded:

  • Prior treatment with efavirenz, 3TC, an NNRTI, or an protease inhibitor.
  • Prior antiretroviral agent within 14 days of initiating study treatment.
  • Prior treatment (within 30 days of initiating study treatment) with any other experimental drug for any indication.

Patients must:

  • Have a diagnosis of HIV infection.
  • Have greater than or equal to 50 cell/mm3.
  • Have a life expectancy greater than or equal to 12 months.
  • Be post-pubescent.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment

Interventions

06

Study locations

41 sites
  • Phoenix Body Positive
    Phoenix, Arizona 85016, United States
  • Arizona Clinical Research Ctr Inc
    Tucson, Arizona 85712, United States
  • Richard Stryker
    Beverly Hills, California 90210, United States
  • Paul Cimoch
    Irvine, California 92618, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 90027, United States
  • Kraus Med Group
    Los Angeles, California 90036, United States
  • Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr
    Los Angeles, California 90059, United States
  • Blick Med Associates
    Stamford, Connecticut 06901, United States
  • Novum Inc
    Washington, District of Columbia 20037, United States
  • Bach and Godofsky
    Bradenton, Florida 34205, United States
  • Community Research Initiative of South Florida
    Coral Gables, Florida 33146, United States
  • Boulevard Comprehensive Care Ctr
    Jacksonville, Florida 32209, United States
  • Larry Marc Bush / c/o Sally Yantis
    Lake Worth, Florida 33463, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Ctr for Quality Care
    Tampa, Florida 33609, United States
  • Daniel Seekins
    Tampa, Florida 33614, United States
  • Infectious Disease Research Institute
    Tampa, Florida 33614, United States
  • Treasure Coast Infectious Disease Consultants
    Vero Beach, Florida 32960, United States
  • Georgia Research Associates
    Atlanta, Georgia 30342, United States
  • Med College of Georgia
    Augusta, Georgia 30912, United States
  • Infectious Diseases
    Indianapolis, Indiana 46202, United States
  • Univ of Kentucky Med Ctr
    Lexington, Kentucky 40536, United States
  • Kansas City AIDS Research Consortium
    Kansas City, Missouri 64111, United States
  • Univ of Nebraska Med Ctr / HIV Clinic
    Omaha, Nebraska 681985400, United States
  • Univ Med Ctr / HIV Wellness Ctr
    Las Vegas, Nevada 89102, United States
  • Community Research Initiative on AIDS
    New York, New York 10001, United States
  • Clinical Directors Network / HIV/AIDS Program Manager
    New York, New York 10011, United States
  • Wake Forest Univ School of Medicine
    Winston Salem, North Carolina 27157, United States
  • Remington-Davis Inc
    Columbus, Ohio 43215, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • The Miriam Hosp
    Providence, Rhode Island 02906, United States
  • Research Services 2000 Inc
    Dallas, Texas 75208, United States
  • Division of Infectious Disease / Dept of Internal Medicine
    Dallas, Texas 752359113, United States
  • Research Services 2000 Inc
    Fort Worth, Texas 76103, United States
  • Montrose Clinic
    Houston, Texas 77006, United States
  • UT-Health Science Ctr
    Houston, Texas 77030, United States
  • Diagnostic Clinic of San Antonio
    San Antonio, Texas 78229, United States
  • Oyster Point Med Specialists
    Newport News, Virginia 23606, United States
  • Novum Inc / Pharmaceutical Research Services
    Seattle, Washington 98122, United States
  • Infectious Diseases Associates
    Milwaukee, Wisconsin 53215, United States
  • Javier O Morales Ramirez
    San Juan, 00909, Puerto Rico
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002410
Lead sponsor
Dupont Merck
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 1998. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Indinavir · Lamivudine · Zidovudine

Start the discussion